Koga S, Shimizu N, Maeta M, Hamazoe R, Izumi A
Gan To Kagaku Ryoho. 1983 Feb;10(2 Pt 2):358-65.
Recently, there is a renewed interest in the efficacy of hyperthermia in human cancer therapy. Based on the results of our experimental studies, we treated far-advanced cancer patients with extracorporeally induced total-body hyperthermia (TBHT) or continuous hyperthermic peritoneal perfusion (CHPP). In the TBHT combined with anticancer chemotherapy, a partial remission was observed in 4 (25.0%) of 16 far-advanced cancer patients. However, the improvement of survival time was unsatisfactory. The CHPP combined with anticancer chemotherapy was performed in 23 gastric cancer patients with peritoneal dissemination. In 6 of them, subjective complaints were improved, but the remarkable prolongation of survival time was not obtained. If in the future hyperthermochemotherapy is performed for cancer recurrence in early stage, more favourable results may be expected.
最近,人们对热疗在人类癌症治疗中的疗效重新产生了兴趣。基于我们的实验研究结果,我们采用体外诱导全身热疗(TBHT)或持续热灌注腹腔化疗(CHPP)治疗了晚期癌症患者。在TBHT联合抗癌化疗中,16例晚期癌症患者中有4例(25.0%)出现部分缓解。然而,生存时间的改善并不理想。23例伴有腹膜播散的胃癌患者接受了CHPP联合抗癌化疗。其中6例患者的主观症状有所改善,但未观察到生存时间的显著延长。如果未来对早期癌症复发进行热化疗,可能会获得更理想的结果。